SZABO SCANDIC

Part of Europa Biosite

Produktinformation

Forschungsprodukte & Biochemikalien

Zellkultur & Verbrauchsmaterial

Diagnostik & molekulare Diagnostik

 Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

immunostep we know how

Address: Avda. Universidad de Coimba, s/n
Cancer Research Center (C.I.C.)
Campus Miguel de Unamuno
37007 Salamanca (Spain)
Tel. / Fax: (+34) 923 294 827
E-mail: info@immunostep.com
www.immunostep.com

Product: PE Anti-Human CD33
Cat. Ref: 33PE-100T
Reagent provided: 100 test (20µl / test)
Description: Monoclonal Mouse Anti-Human CD33 PE is recommended for use in flow cytometry for identification of myeloid progenitors and mast cells. The conjugate is provided in liquid form in buffer containing Antibody Stabilizer, PBS, pH 7,4.
Clone: HIM3-4
Isotype: IgG1
HLDA: 5th International Workshops on Human Leucocyte Differentiation, WS Code MA112
Fluorochrome: R-Phycoerythrin, R-PE (Ex.: 496, 564 nm/Em-Max: 578 nm). The fluorophore is excited by the blue laser (488 nm), yellow/green (532-561 nm) laser. It is recommended to use a 556 LP dichroic mirror and 585/42 or 575/26 band pass filter detector-equipped flow cytometer.

INTENDED PURPOSE.

CD33 PE is a monoclonal antibody conjugated that may be used to identification of human myelomonocytic cells by flow cytometry..

TECHNICAL SUMMARY.

Reactivity: The monoclonal antibody is directed against the CD33-antigen (belonging to the Ig-supergene family), which is expressed on human myelomonocytic cells. The monoclonal antibody reacts in the bone marrow from myeloblasts up to myelocytes. CD33-antigen is found on CFU-GEMM, CFU-GM, CFU-G, CFU-M and with erythroid CFU-E but not on earlier precursors. The monoclonal antibody does not react with normal human peripheral B-cells, T-cells and platelets. The monoclonal antibody reacts weakly with blast cells in 70% of patients with Acute Myeloid Leukaemia (AML) and in 30% of adult patients with Acute Lymphoblastic Leukaemia (ALL).

Specificity: The antigen is a single chain transmembrane glycoprotein of molecular mass 67 kDa expressed on monocytes, myeloid progenitor cells and myeloid leukaemias. The antigen has homology with CD22 and myelin associated glycoprotein. CD33 appears very early on myelomonocytic precursors and is expressed in both the myeloid and monocytic cell lineages.

CLINICAL RELEVANCE

CD33 is absent from pluripotent stem cells but appears on myelomonocytic precursors after CD34. It then continues to be expressed on both the myeloid and monocyte lineages.

PRINCIPLES OF THE TEST.

Immunostep CD33 PE monoclonal antibodies bind to the surface of cells that express the CD33 antigen. To identify these cells, peripheral blood leucocytes are incubated with the antibodies and red blood cells are lysed before washing to remove unbound antibodies. Cells are analysed by flow cytometry with 488 nm or 532 nm laser.

REAGENTS.

Cluster Designation:	CD33
Clone:	HIM3-4
Isotype:	IgG1
Species:	Mouse
Composition:	IgG1 heavy chain Kappa light chain
Source:	Hybridome Cells
Method of Purification:	Affinity chromatography
Fluorochrome:	R- Phycoerythrin (PE)

immunostep
we know how

Address: Avda. Universidad de Coimba, s/n
Cancer Research Center (C.I.C.)
Campus Miguel de Unamuno
37007 Salamanca (Spain)
Tel. / Fax: (+34) 923 294 827
E-mail: info@immunostep.com
www.immunostep.com

	Excitation wavelength 488 nm Emission wavelength 575 nm
Molar composition:	PE/protein 1 ± 0,5
Reagents contents:	2 ml vial containing monoclonal antibody for 100 tests. The conjugate is provided in aqueous buffered solution containing protein stabilizer, and ≤0.09% sodium Azide
Reagent preparation:	Ready to use.

1. STATEMENTS, SETTINGS AND WARNINGS.

- Reagents contain sodium azide. Sodium azide under acid conditions yields hydrazoic acid, an extremely toxic compound. Azide compounds should be diluted with running water before being discarded. These conditions are recommended to avoid deposits in plumbing where explosive conditions may develop.
- Light exposure should be avoided. Use dim light during handling, incubation with cells and prior to analysis.
- Do not pipet by mouth.
- Samples should be handled as if capable of transmitting infection. Appropriate disposal methods should be used.
- The sample preparation procedure employs a fixative (formaldehyde). Contact is to be avoided with skin or mucous membranes.
- Do not use antibodies beyond the stated expiration dates of the products.
- Deviations from the recommended procedure enclosed within this product insert may invalidate the results of testing.
- FOR *IN VITRO* DIAGNOSTIC USE
- For professional use only.

2. APPROPIATE STORAGE CONDITIONS.

- R-Phycoeritryn (RPE)
  Keep in dark place at 2-8°C. DO NOT FREEZE.

3. EVIDENCE OF DETERIORATION.

- Reagents should not be used if any evidence of deterioration or substantial loss of reactivity is observed. For more information, please contact with our technical service: tech@immunostep.com

- The normal appearance of the PE conjugated monoclonal antibody is a clear, pink-red liquid.

4. SPECIMEN COLLECTION.

Collect venous blood samples into blood collection tubes using an appropriate anticoagulant (EDTA or heparin). For optimal results the sample should be processed within 6 hours of venipuncture. EDTA, ACD or heparin may be used if the blood sample is processed for analysis within 30 hours of venipuncture. ACD or heparin, but not EDTA, may be used if the sample is not processed within 30 hours of venipuncture. Samples that cannot be processed within 48 hours should be discarded.

If venous blood samples are collected into ACD for flow cytometric analysis, a separate venous blood sample should be collected into EDTA if a CBC is required.

Unstained anticoagulated blood should be retained at 20- 25oC prior to sample processing. Blood samples that are hemolyzed, clotted or appear to be lipemic, discoloured or to contain interfering substances should be discarded.

Refer to "*Standard Procedures for the Collection of Diagnostic Blood Specimens*" published by the National Committee for Clinical Laboratory Standards (NCCLS) for additional information on the collection of blood specimens.

5. SAMPLE PREPARATION.

a) Add 20 µL of CD33 PE and mix gently with a vortex mixer. The 20 µL is a guideline only; the optimal volume should be determined by the individual laboratory

immunostep
we know how

Address: Avda. Universidad de Coimba, s/n
Cancer Research Center (C.I.C.)
Campus Miguel de Unamuno
37007 Salamanca (Spain)
Tel. / Fax: (+34) 923 294 827
E-mail: info@immunostep.com
www.immunostep.com

b) Transfer 100 µL of anticoagulated (EDTA) blood to a 12 x 75 mm polystyrene test tube (10^6 cells).
c) The recommended negative control is a non-reactive PE-conjugated antibody of the same isotype.
d) Incubate in the dark at room temperature (20-25 °C) for 15 minutes or at 4 °C for 30 minutes.
e) Add Lysing Solution according to the manufacturer's directions to each sample and mix gently with a vortex mixer.
f) Centrifuge at 540g for 5 minutes. Gently aspirate the supernatant without disturbing the cell pellet and discard it leaving approximately 50 µL of fluid.
g) Add 2 mL 0.01 mol/L PBS (It better that it containing 0,5 % bovine serum albumin) and resuspend the cells. Mix well.
h) Centrifuge at 540g for 5 minutes. Gently aspirate the supernatant and discard it leaving approximately 50 µL of fluid.
i) Resuspend pellet in an appropriate fluid for flow cytometry, e.g. 0.3 mL PBS + 0,5 % BSA.

Analyse on a flow cytometer or store at 2-8 °C in the dark until analysis. Samples can be run up to 3 hours after lysis.

6. MATERIALS REQUIRED BUT NOT SUPPLIED.

Isotype control reagents:	Mouse IgG1: PE
Leucocyte gating reagent:	Mouse anti-human CD45: FITC/CD14 APC
Serofuge or equivalent centrifuge	
12 x 75 mm polypropylene centrifuge tubes	
Micropipette capable of dispensing 5 µl, 20 µl, 100 µl, and 500 µl volumes	
Blood collection tubes with anticoagulant	
Phosphate buffered saline (PBS)	
Trypan Blue or propidium iodide, 0.25% (w/v) in PBS for the determination of cell viability	
Lysing Solution	
Fixing Solution	
Flow cytometer:	Becton Dickinson FACSCaliburTM, Coulter Profile or equivalent 488 nm ion argon laser or 561-nm (Yellow-Green) laser, 556 LP filter, 585/42 or 575/26 detector-equipped and appropriate computer hardware and software.

7. INTERPRETATION OF RESULTS.

- *FLOW CYTOMETRY*

Analyze antibody-stained cells on an appropriate flow cytometer analyzer according to the manufacturer instructions. The right angle light scatter or other scatter (SSC) versus forward angle light scatter (FSC) is collected to reveal the lymphocyte cell cluster. A gate is drawn for the lymphocyte cluster (lymphocyte bitmap). The fluorescence attributable to the PE- conjugated monoclonal antibody is collected, and the percentage of antibody-stained T lymphocytes is determined. An appropriate PE-conjugated isotypic control of the same heavy chain immunoglobulin class and antibody concentration must be used to estimate and correct for non-specific binding to lymphocytes. An analysis region is set

Address: Avda. Universidad de Coimba, s/n
Cancer Research Center (C.I.C.)
Campus Miguel de Unamuno
37007 Salamanca (Spain)
Tel. / Fax: (+34) 923 294 827
E-mail: info@immunostep.com
www.immunostep.com

to exclude background fluorescence and to include positively stained cells. The following histograms are representative of cells.



The histogram is biparametric representations (Side Scatter versus Fluorescence Intensity) of a lysate normal whole blood sample gated on leucocytes. Human peripheral blood lymphocytes were stained with CD33 PE and CD45 PerCP.

Cells were analyzed on a FACSCalibur (Becton Dickinson, San Jose, CA) flow cytometer, using Cell Quest acquisition software and PAINT-A-GATE. PRO, analysis software.

8. QUALITY CONTROL PROCEDURES.

Non-specific fluorescence identified by the FITC conjugated isotypic control is usually less than 2% in normal individuals. Non-specific fluorescence identified by the PE and APC conjugated isotypic controls are usually less than 4% in normal individuals. If the background level exceeds these values, test results may be in error. Increased non-specific fluorescence may be seen in some disease states.

A blood sample from each normal and abnormal donor should be stained with the CD45 Pan-lymphocyte and CD14 Pan-monocyte monoclonal antibodies. When used in combination, these reagents assist in identifying the lymphocyte analysis region, and distinguish lymphocytes from monocytes, granulocytes and unlysed or nucleated red cells and cellular debris.

A blood sample from a healthy normal donor should be analyzed as a positive control on a daily basis or as frequently as needed to ensure proper laboratory working conditions. Each laboratory should establish their own normal ranges, since values obtained from normal samples may vary from laboratory to laboratory.

An appropriate isotype control should be used as a negative control with each patient sample to identify non-specific Fc binding to lymphocytes. An analysis region should be set to exclude the non-specific fluorescence identified by the isotypic control, and to include the brighter fluorescence of the lymphocyte population that is identified by the specific antibody.

Refer to the appropriate flow cytometer instrument manuals and other available references for recommended instrument calibration procedures.

9. LIMITATIONS OF THE PROCEDURE.

- Incubation of antibody with cells for other than the recommended time and temperature may result in capping or loss of antigenic determinants from the cell surface.
- The values obtained from normal individuals may vary from laboratory to laboratory; therefore, it is recommended that each laboratory establish its own normal range.
- Abnormal cells or cell lines may have a higher antigen density than normal cells. This could, in some cases, require the use of a larger quantity of monoclonal antibody than is indicated in the procedures for Sample Preparation.
- Blood samples from abnormal donors may not always show abnormal values for the percentage of lymphocytes stained with a given monoclonal antibody. Results obtained by flow cytometric analysis should be considered in combination with results from other diagnostic procedures.
- When using the whole blood method, red blood cells found in some abnormal donors, as well as nucleated red cells found in normal and abnormal donors may be resistant to lysis by lysing

immunostep
we know how

Address: Avda. Universidad de Coimba, s/n
Cancer Research Center (C.I.C.)
Campus Miguel de Unamuno
37007 Salamanca (Spain)
Tel. / Fax: (+34) 923 294 827
E-mail: info@immunostep.com
www.immunostep.com

solutions. Longer red cell lysis periods may be needed to avoid the inclusion of unlysed red cells in the lymphocyte gated region.

- Blood samples should not be refrigerated or retained at ambient temperature for an extensive period (longer than 24-30 hours) prior to incubating with monoclonal antibodies.
- Accurate results with flow cytometric procedures depend on correct alignment and calibration of the laser, as well as proper gate settings.
- Due to an unacceptable variance among the different laboratory methods for determining absolute lymphocyte counts, an assessment of the accuracy of the method used is necessary.
- Al results need to be interpreted in the context of clinical features, complete immunophenotype and cell morphology, taking due account of samples containing a mixture of normal and neoplastic cells.

10. REFERENCE VALUES.

The cellular elements of human Bone Marrow include lymphocytes, monocytes, granulocytes, red blood cells and platelets.

Nucleated cells Percentage in the Bone Marrow

Cell type	Percentage
Progranulocytes	56,7
Neutrophils	53,6
Myeloblasts	0,9
Promyeloblasts	3,3
Promyelocytes	12,7
Metamyelocytes	15,9
Eosinophils	3,1
Basophils	<0,1
Proerythrocyte	25,6
Proerythrblasts	0,6
Basophil Erythroblast	1,4
Polycromatic Erythroblast	21,6
Ortocromatic Erythroblast	2
Megakaryocytes	<0,2
Lymphocytes	16,2
Plasma cells	2,3
Reticular cells	0,4

Normal human peripheral blood lymphocytes 20-47% (n=150% confidence interval)

Nucleated cells Percentage in Peripheral Blood of a Normal Patient

Cell type	Percentage	Number of event.
Red Blood Count		3,8 - 5,6 X10^{6}/µL
Platelets		150 - 450 X10^{3}/µL
White Blood Count (WBC)		4.3 - 10.0 X10^{3}/µL
Neutrophils	57 – 67 %	1,5 - 7.0 X10^{3}/µL
Lymphocytes*	25 – 33 %	1.0 - 4.8 X10^{3}/µL
T cell	56 – 82 % of lymphocytes	
T cell CD4+	60 % of T cells	
T cell CD8+	40 % of T cells	
Cell NK+	6 – 33 of lymphocytes	
B cell	7.7 – 22 of lymphocytes	
Monocytes	3 – 7 %	0.28 - 0.8 X10^{3}/µL
Eosinophils	1 – 3 %	0.05 – 0,25 X10^{3}/µL
Basophils	0 – 0,075 %	0,015 – 0,05 X10^{3}/µL
Reticulocyte	0,5 – 1,5 % of total Red	

immunostep
we know how

Address: Avda. Universidad de Coimba, s/n
Cancer Research Center (C.I.C.)
Campus Miguel de Unamuno
37007 Salamanca (Spain)
Tel. / Fax: (+34) 923 294 827
E-mail: info@immunostep.com
www.immunostep.com

	Blood Cell	

Expected values for pediatrics and adolescents have not been established.

The values obtained from normal individuals may vary from laboratory to laboratory; therefore, it is recommended that each laboratory establish its own normal range.

11. PERFORMANCE CHARACTERISTICS.

- *SPECIFICITY*

Anti CD33 clone HIM3-4, was included in the fifth International Workshops on Human Leucocyte Differentiation Antigens, WS code MA112.

CD33 is expressed on myelomonocytic cells cells. To evaluate the reagent's specificity (cross-reactivity with other cell populations), 10 blood samples from healthy donors were studied, stained with an adequate isotype control and the MAb to study.

Blood samples obtained from healthy normal donors of Caucasian were stained with Immunostep CD33 PE monoclonal antibody. Non-specific fluorescence identified by the PE-conjugated isotypic control IgG1 was analysed. Cells contained in platelets, erythrocytes, monocytes and T lymphocyte regions were selected for analysis. Blood samples were processed by a Staining Cell Surface Antigens for Flow Cytometry Protocol described in Section 5.

The results obtained are shown in the following table:

Descriptive Statistics

	N	Minimum	Maximum	Mean	Std. Deviation
% Isotype control	10	,00	,53	,1840	,19699
% Platelets	10	,04	,45	,2380	,14711
% T Lymphocyte	10	,00	,12	,0360	,04551
% Erythrocytes	10	,01	,46	,1660	,14645
% B Lymphocyte	10	,00	,03	,0070	,00949
Valid N (listwise)	10				

- *SENSIBILITY*

Sensitivity of the Immunostep CD33 monoclonal antibodies was determined by staining a blood sample from donor. Dilutions of a peripheral blood sample were made to check the concentration scale of stained cells obtained. The results show an excellent correlation level between the results obtained and expected based on the dilution used.

To determine the consistency of the conjugated monoclonal antibody as opposed to small variations (but deliberate). It provides an indication of its reliability during its normal use.

Model Summary[b]

R	R Square	Adjusted R Square	Std. Error of the Estimate	Linear regression
,996[a]	,993	,992	3,09025	y = 1,000x + 1,965

a. Dependent Variable: % Obtained

immunostep
we know how

Address: Avda. Universidad de Coimba, s/n
Cancer Research Center (C.I.C.)
Campus Miguel de Unamuno
37007 Salamanca (Spain)
Tel. / Fax: (+34) 923 294 827
E-mail: info@immunostep.com
www.immunostep.com



The results show an excellent correlation between the results obtained and expected based on the dilution used. CD33 PE sensibility was demonstrated from 1×10^5 to 1×10^6 cells in 1×10^6 total cells.

- *REPRODUCIBILITY*

Reproducibility for the Immunostep CD33 PE-conjugated monoclonal antibodies was determined by performing 10 replicated determinations of each antibody in each of three ranges of lymphocytes; high, medium and low. Thus, a total of 30 determinations were performed. In this manner, reproducibility was demonstrated throughout the entire measuring range.

The 10 determinations for each range were performed by the staining, processing and analysis of 10 separate samples. Lymphocytes CD33+ were selected for the analysis of percent cells stained in each of the three ranges.

To perform this study, anticoagulated blood was obtained from three different donors expressing a high, medium and low percentage of Lymphocytes.

Descriptive Statistics

Range		N	Minimum	Maximum	Mean	Std. Deviation
High	Porcentage	10	8,67	9,81	9,0590	,38220
	IMF	10	15555	17283	16226,20	566,665
	Valid N (listwise)	10				
Medium	Porcentage	10	5,48	6,13	5,7570	,20320
	IMF	0				
	Valid N (listwise)	0				
Low	Porcentage	10	4,93	5,55	5,2560	,21732
	IMF	0				
	Valid N (listwise)	0				

**Note:* Data analyzed with SPSS for Windows 11.0.1*

immunostep we know how

Address: Avda. Universidad de Coimba, s/n
Cancer Research Center (C.I.C.)
Campus Miguel de Unamuno
37007 Salamanca (Spain)
Tel. / Fax: (+34) 923 294 827
E-mail: info@immunostep.com
www.immunostep.com

- *WITHIN-LABORATORY PRECISION (INTRA-ASSAY)*

To determine the repeatability of staining with this product, 6 different samples were stained with two different lots of this reagent. For each sample two different values were obtained: the mean fluorescence intensity (MFI) and the percentage of positive cells. The mean of the standard deviation of each sample for the MFI and the percentage of positive were calculated. Lymphocytes CD22+/CD45+ cells were selected in the analysis.

The results of the analysis are shown in the following chart:

	Average Mean	Average Std. Deviation	Average %CV
% positive	5,1625	0,1591	3,0005
IMF	2896,7500	220,2638	7,2681
Valid N (listwise)	6	6	6

As shown in the table, the results show excellent repeatability from lot to lot, both average %CV percentages of positive cells and MFI as show values.

12. BIBLIOGRAPHY.

1. Knapp,W.,B.Dorken,E.P.Rieber,et al .,eds.1989.Leucocyte Typing IV:White Cell Differentiation Antigens,Oxford University Press,New York.
2. Favaloro,E.J.,K.F.Bradstock,A.Kabral,et al .1988.Further characterization of human myeloid antigens (gp 160,95,gp150;gp67):investigation of epitopic heterogeneity and non-haemopoietic distribution using panels of monoclonal antibodies and belonging to CD-11b,CD-13 and CD-33.Br.J.Haematol .69:163.
3. Favaloro,E.J.,N.Moriatis,J.Koutls,et al .1989.Endothelial cells and normal circulating haemopoietic cells share a number of surface antigens.Thromb.and Haemo .61:217.
4. Freeman,S.D.,S.Kelm,E.K.Barber,et al .1995.Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules.Blood 85:2005.
5. Nakamura,Y.,M.Noma,M.Kidoro,et al.1994.Expression of CD33 on normal human activated T lymphocytes [letter].Blood 83:1442. 10 CA).